Stephen L. Silvestro - 21 Aug 2025 Form 4 Insider Report for OptimizeRx Corp (OPRX)

Reporting relationship: Chief Executive Officer
Issuer ticker: OPRX
Reported as of: 21 Aug 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 25 Aug 2025, 16:32:47 UTC
Prior SEC filing: 19 May 2025
Next SEC filing: 07 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ Marion Odence-Ford, by Power of Attorney

Key filing fact

Stephen L. Silvestro filed Form 4 for OptimizeRx Corp (OPRX) on 25 Aug 2025.

Key facts

This page summarizes Stephen L. Silvestro's Form 4 filing for OptimizeRx Corp (OPRX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 25 Aug 2025, 16:32.

Change

Previous filing in this sequence was filed on 19 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001773461 Primary reporting owner

Silvestro Stephen L

Relationship: Chief Executive Officer
Address: C/O OPTIMIZERX CORPORATION, 260 CHARLES STREET, SUITE 302, WALTHAM
Signature: /s/ Marion Odence-Ford, by Power of Attorney
Signature date: 25 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OPRX transaction

Common Stock

Award

Transaction value: $0
Shares: +15,625
Change %: +9.3%
Price: $0.000000
Shares after: 183,887
Date: 21 Aug 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OPRX transaction Derivative

Stock Option

Award

Transaction value: $0
Shares: +35,156
Change %
Price: $0.000000
Shares after: 35,156
Date: 21 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 35,156
Exercise price: $16.14
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in three equal annual installments beginning on August 21, 2026, which is the first anniversary of the grant date.

Footnote F2

The stock option vests in three equal annual installments beginning August 21, 2026, the first anniversary of the grant date.

SEC remarks

The filing of this Statement shall not be construed as an admission (a) that the person filing this Statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this Statement, or (b) that this Statement is legally required to be filed by such person